Nivolumab for adjuvant treatment of stage IB-IIIA non-small cell lung cancer

Nivolumab is in clinical development for the adjuvant treatment of stage IB-IIIA non-small cell lung cancer (NSCLC). NSCLC occurs due to tumours forming in the lung and is the most common form of lung cancer. Stage IB-IIIA disease comprises of a range of tumours from 3cm to larger than 7cm in size and have little or no spread to areas of the body close to the lung. NSCLC at early stages may not present symptoms, however patients may also have a cough that changes or gets worse, breathlessness, chest or shoulder pain and may be coughing up blood. Surgery is mostly used to treat NSCLC, and the aim of adjuvant treatment (treatment following a surgical procedure) is to reduce the risk of disease recurrence.